Maravai LifeSciences (NASDAQ: MRVI) reported Q2 EPS of ($0.05), $0.06 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $68.91 million versus the consensus estimate of $71.13 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.